Nanomedicine in Lung Cancer Immunotherapy

Doroudian, Mohammad; Zanganeh, Saba; Abbasgholinejad, Elham; Donnelly, Seamas C

doi:10.3389/fbioe.2023.1144653

Cited by 20 publications

(10 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to reports on the active capture of PLGA particles of 500 nm in size by macrophages [ 20 ] and the great biodistribution of PLGA particles in the tissues [ 49 ], the intraperitoneal injection of PLGA particles demonstrated the prominent capture in the spleens and livers (the reticuloendothelial system), perhaps by splenic macrophages (at the marginal zones [ 50 ]) and Kupffer cells (at the portal areas and hepatic sinuses [ 1 , 51 ]). The specific size and shape of BAM15 particles might be responsible for the more selective uptake by macrophages over neutrophils [ 33 , 52 ], which was possibly responsible for a less anti-inflammatory impact of BAM15 particles on neutrophils than macrophages. On the other hand, the more dominant impact of BAM15 particles against M1 than M2 macrophages might be due to the diverse impact of particle sizes [ 53 ], different molecular signals [ 54 ], and/or phagocytosis activities [ 55 ] between M1 versus M2.…”

Section: Discussionmentioning

confidence: 99%

Polymeric Particle BAM15 Targeting Macrophages Attenuates the Severity of LPS-Induced Sepsis: A Proof of Concept for Specific Immune Cell-Targeted Therapy

Udompornpitak,

Bhunyakarnjanarat,

Saisorn

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Macrophage polarization requires different energy sources and metabolic processes. Therefore, cell energy interference to alter macrophage functions has been proposed as a treatment for severe inflammatory diseases, including sepsis. In this study, targeting cell energy using BAM15 (a mitochondrial uncoupling agent) in human THP-1 and mouse RAW264.7 macrophages prominently interfered with M1 but not M2 polarization. Free BAM15 (BAM15) and BAM15-loaded PLGA particles (BAM15 particles) reduced the inflammatory response of M1 macrophages and enhanced the expression of M2 signature genes with the restoration of mitochondrial activity (extracellular flux analysis) in RAW264.7 cells. Furthermore, BAM15 particles but not BAM15 showed specific effects on the inflammatory response of macrophages but not neutrophils, and the particles were actively captured by splenic and liver macrophages in vivo. Administration of BAM15 and BAM15 particles attenuated the severity of sepsis in LPS-induced sepsis mice. Interestingly, BAM15 particles but not BAM15 alleviated LPS-induced liver injury by reducing hepatic inflammation. Our findings substantiate the superior efficacy of macrophage-targeted therapy using a BAM15 particle-delivery system and provide further support for clinical development as a potential therapy for severe inflammatory diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Polymeric Particle BAM15 Targeting Macrophages Attenuates the Severity of LPS-Induced Sepsis: A Proof of Concept for Specific Immune Cell-Targeted Therapy

Udompornpitak,

Bhunyakarnjanarat,

Saisorn

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Immune checkpoint inhibitors (ICIs) have the ability to block inhibitory pathways, suppressing the immune response to cancer and restoring as well as maintaining anti-tumor immunity. Immune checkpoints (ICPs) are proteins produced by certain immune cells (e.g., T cells) and cancer cells, including CTLA-4, PD-1, PD-L1, TIM-3, CD73, and TIGIT ( Doroudian et al, 2023 ). However, only a small proportion of patients respond to these therapies, while the majority do not, leading to drug resistance and tumor recurrence.…”

Section: Emerging Lung Cancer Immunotherapymentioning

confidence: 99%

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

Zhang,

Li,

Guo

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Amidst a global rise in lung cancer occurrences, conventional therapies continue to pose substantial side effects and possess notable toxicities while lacking specificity. Counteracting this, the incorporation of nanomedicines can notably enhance drug delivery at tumor sites, extend a drug’s half-life and mitigate inadvertent toxic and adverse impacts on healthy tissues, substantially influencing lung cancer’s early detection and targeted therapy. Numerous studies signal that while the nano-characteristics of lung cancer nanomedicines play a pivotal role, further interplay with immune, photothermal, and genetic factors exist. This review posits that the progression towards multimodal combination therapies could potentially establish an efficacious platform for multimodal targeted lung cancer treatments. Current nanomedicines split into active and passive targeting. Active therapies focus on a single target, often with unsatisfactory results. Yet, developing combination systems targeting multiple sites could chart new paths in lung cancer therapy. Conversely, low drug delivery rates limit passive therapies. Utilizing the EPR effect to bind specific ligands on nanoparticles to tumor cell receptors might create a new regime combining active-passive targeting, potentially elevating the nanomedicines’ concentration at target sites. This review collates recent advancements through the lens of nanomedicine’s attributes for lung cancer therapeutics, the novel carrier classifications, targeted therapeutic modalities and their mechanisms, proposing that the emergence of multi-target nanocomposite therapeutics, combined active-passive targeting therapies and multimodal combined treatments will pioneer novel approaches and tools for future lung cancer clinical therapies.

show abstract

“…Lung cancer is the leading cause of cancer deaths world-wide [ 1 ]. In China, lung cancer has become the fastest growing malignancy in terms of incidence rate and mortality in the last 30 years [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Analysis of the incidence and influencing factors of abdominal distension in postoperative lung cancer patients in ICU based on real-world data: a retrospective cohort study

Liu,

Tang,

Wang

et al. 2024

BMC Surg

View full text Add to dashboard Cite

Background Abdominal distension is a relatively common complication in postoperative lung cancer patients, which affects patients’ early postoperative recovery to varying degrees. However, the current status of the incidence of abdominal distension in postoperative lung cancer patients and the affecting factors are not well understood. This study aims at exploring the incidence of abdominal distension in postoperative lung cancer patients in ICU based on real-world data and analyzing its influencing factors. Methods A retrospective cohort study was conducted, encompassing patients who underwent lung cancer resections in the Lung Cancer Center of West China Hospital of Sichuan University from April 2020 to April 2021. Nevertheless, patients younger than 18 years and those whose information was limited in medical records were excluded. All data were obtained from the hospital HIS system. In this study, the influencing factors of abdominal distension were analyzed by univariate analysis and multiple logistic regression methods. Results A total of 1317 patients met eligibility criteria, and were divided into the abdominal distended group and the non-distended group according to whether abdominal distension occurred after surgery. Abdominal distension occurred in a total of 182 cases(13.8%). The results of the univariate analysis showed that, compared with the non-distended group, the abdominal distended group had these features as follows: more women (P = 0.021), older (P = 0.000), lower BMI (P = 0.000), longer operation duration (P = 0.031), more patients with open thoracotomy (P = 0.000), more patients with pneumonectomy (p = 0.002), more patients with neoadjuvant chemotherapy (P = 0.000), more days of hospitalization on average (P = 0.000), and higher costs of hospitalization on average (P = 0.032). Multifactor logistic regression analysis showed that sex (OR = 0.526; 95% CI = 0.378 ~0.731), age (OR = 1.154; 95%CI = 1.022 ~1.304) and surgical approach (OR = 4.010; 95%CI = 2.781 ~5.781) were independent influencing factors for the occurrence of abdominal distension in patients after lung cancer surgery in ICU. Conclusions The incidence of abdominal distension was high in postoperative lung cancer patients in ICU, and female, older and patients with open thoracotomy were more likely to experience abdominal distension. Trial registration The study was approved by the Chinese Clinical Trials Registry (registration number was ChiCTR2200061370).

show abstract

Nanomedicine in Lung Cancer Immunotherapy

Cited by 20 publications

References 93 publications

Polymeric Particle BAM15 Targeting Macrophages Attenuates the Severity of LPS-Induced Sepsis: A Proof of Concept for Specific Immune Cell-Targeted Therapy

Polymeric Particle BAM15 Targeting Macrophages Attenuates the Severity of LPS-Induced Sepsis: A Proof of Concept for Specific Immune Cell-Targeted Therapy

Moving beyond traditional therapies: the role of nanomedicines in lung cancer

Analysis of the incidence and influencing factors of abdominal distension in postoperative lung cancer patients in ICU based on real-world data: a retrospective cohort study

Contact Info

Product

Resources

About